German pharmaceutical company BioNTech said today that it has started testing a possible coronavirus vaccine in volunteers.
The 12 participants in the clinical trial in Germany received doses of the possible BNT162 vaccine since April 23, explained BioNTech, which works with the American Pfizer.
Several pharmaceutical companies compete to find a vaccine for the virus that has caused a pandemic with more than 215,000 deaths and that has infected at least three million people.
In the next phase of the trial, which will involve about 200 people between the ages of 18 and 55, the dose of the drug will begin to increase, BioNTech said in a statement.
The company said it expects to receive authorization from the regulator to start trials in the United States soon.